Chemicals & Small Molecules

Romidepsin, also known as FK228 or depsipeptide, is a potent and selective inhibitor of HDAC1 and HDAC2 , which are associated with the regulation of re-expression of silenced tumor suppressor genes. It was the first HDAC inhibitor to manifest anti-tumor activity and originally isolated from a rod-shaped Gram-negative bacterium, Chromobacterium violaceum, found in a Japanese soil sample. Romidepsin exhibits a stronger inhibition towards HDAC1 and HDAC2 enzymes (class I), removing acetyl groups from the lysine residues of N-terminal histone tails and maintaining a more open and transcriptionally active chromatin state, than HDAC4 and HDAC6 enzymes (class II). Besides HDAC inhibition, romidepsin is also able to induce cell cycle arrest, cellular differentiation, apoptosis and alteration of gene expression in adult malignancies.

Rucaparib, also known as AG-014699 or PF-01367338, is an inhibitor of PARP1 with Ki of 1.4 nM.

Rucaparib, also known as AG-014699 or PF-01367338, is an inhibitor of PARP1 with Ki of 1.4 nM.

Rucaparib, also known as AG-014699 or PF-01367338, is an inhibitor of PARP1 with Ki of 1.4 nM.

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 µM. It has anti-inflammatory and anti-depressant activity in the central nervous system.

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 µM. It has anti-inflammatory and anti-depressant activity in the central nervous system.

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 µM. It has anti-inflammatory and anti-depressant activity in the central nervous system.

Potent CREBBP/EP300 bromodomain inhibitor

Potent CREBBP/EP300 bromodomain inhibitor